Does Azithromycin Gel Prevent Lyme Disease After a Tick Bite? A Critique of the Trial
Preventing Lyme disease after a tick bite remains challenging
Researchers evaluated whether topical azithromycin gel could prevent infection
The trial failed to show meaningful protection against Lyme disease
Patients and clinicians continue searching for simple strategies to prevent Lyme disease following a tick bite. One proposed approach involved applying topical azithromycin gel directly to the bite site. Unfortunately, the findings from this study were disappointing.
This double-blinded, placebo-controlled clinical trial was published in The Lancet Infectious Diseases.
What did the study show?
In a post hoc analysis of 134 subjects, investigators reported that six erythema migrans (EM) rashes may have been prevented after topical application of 10% azithromycin gel following a tick bite.
The investigators also reported delayed onset of EM rashes in two individuals by 33 and 51 days, respectively.
Despite these observations, the trial failed to demonstrate that topical azithromycin gel prevented Lyme disease.
Why the trial findings are limited
The study raises several important questions regarding interpretation.
First, preventing or delaying an EM rash is not necessarily equivalent to preventing infection. A reduction in visible skin manifestations does not prove that bacterial transmission was prevented.
Second, the findings relied partly on post hoc analyses, which are generally considered exploratory rather than definitive.
Third, delaying the appearance of an EM rash may complicate recognition and diagnosis if patients falsely assume the infection risk has passed.
Finally, topical delivery itself may be a limitation. Borrelia burgdorferi may disseminate beyond superficial tissues early in infection, potentially limiting the effectiveness of topical therapies.
Clinical Interpretation
It would be helpful if a simple topical treatment could reliably prevent Lyme disease after a tick bite. However, this trial did not support using azithromycin gel for that purpose.
Clinicians and patients should remain cautious when interpreting interventions that reduce surrogate outcomes without demonstrating meaningful reductions in infection risk.
Patients seeking broader prevention strategies may benefit from reviewing prevention of Lyme disease and understanding how Lyme disease is transmitted.
Clinical Takeaway
This study failed to show that topical azithromycin gel prevented Lyme disease after a tick bite.
While a few EM rashes appeared delayed or absent, the evidence did not support meaningful prevention of infection.
Based on this trial, topical azithromycin gel should not be relied upon as a strategy for preventing Lyme disease following tick exposure.
Related Articles
These related articles explore prevention strategies, tick bite management, and challenges following early Lyme exposure.
Prevention of Lyme disease
How do you get Lyme disease?
Tick bite treatment
Delayed Lyme disease diagnosis
Lyme disease symptoms guide
References
- Schwameis M, et al. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial. Lancet Infect Dis. 2016.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
Thank you for this post, Dr Cameron. This was widely reported in the press as being a trial which showed that the gel had “promise” as a treatment for infected bites. As here: https://www.news-medical.net/news/20161220/Antibiotic-gel-shows-promise-in-preventing-onset-of-Lyme-borreliosis-following-tick-bite.aspx
It is a shame the gel failed to work
Is Azithromycin in tablet form affective to treat Lyme?
Oral Zithromax has been effective in most studies. Doxycycline beat Zithromax in on study my Massaroti in 1992.
Because the company making the gel was able to get special status from CDC, called QIDPb status, they get two tries at doing a stage III clinical trial such as this. So long as they have the money, they a redo to look only at the subgroup that showed some benefit. This worries me, because doing a placebo controlled study of high risk tick bites resembles Tuskegee to me: they are knowingly allowing the placebo group to get sick, in order to get a statistically more favorable outcome. Even if the gel helps a segment of people, there is no way for them to identify themselves in advance, so if it’s approved, everybody, not just the subgroup, will potentially use this, and forgo oral antibiotics. One of their medical advisors is Dr. Wormser. I think they might potentially raise the money because the product would be over the counter, this saving instance companies money they would have spent on doxycycline or Amoxicillin.
I also have concerns with trying to sell a cream based on subgroup analysis.